Welcome, visitor! [ Login

Dragon Announces Update on the Letter of Intent to Merge with Oriental Wave Holding Ltd.


Dragon Pharmaceutical Inc. (TSX: DDD, OTC BB: DRUG) (“Dragon”) today updates its previously announced Letter of Intent to merge with Oriental Wave Holding Limited (“Oriental Wave”).

Oriental Wave’s auditor, an accounting firm registered with the Public Company Accounting Oversight Board, has completed its audit and issued its report on Oriental Wave’s 2003 financial statements. Oriental Wave’s consolidated revenues and earnings were US$26 million and US$7.5 million for the year ended December 31, 2003. Revenues primarily consisted of sales by Oriental Wave’s Chemical Drug division. In January 2004, Oriental Wave’s Clavulanic Acid facility of the Chemical Intermediate division commenced production, operation and sales which will be reflected in 2004. Another facility for Chemical Intermediate division producing 7-ACA is under final construction and is expected to start operations during the third quarter of 2004.

Dragon would like to further clarify that, if the proposed merger is consummated, it is anticipated that Dragon, the surviving company, will continue to be a company listed on the Toronto Stock Exchange (Ticker: DDD) and quoted on Over-the-counter Bulletin Board. (Ticker: DRUG).

“The proposed merger will be an important milestone for the history of Dragon by transforming into a serious player in the global pharmaceutical industry with proven product lines, significant infrastructure, operations and sizable revenues from the prominent Chinese market and a competitive edge to be successful in the international market covering both developing and developed countries. Our current listing status in both U.S. and Canada stock markets would allow the combined company to access the North American capital market, where there is re-emerging investor interest in both biotech and chemical generic drug sectors as well as in companies with material access to the significant Chinese pharmaceutical market.”
said, Dr. Alexander Wick, President and CEO of Dragon.

Dragon’s and Oriental Wave’s proposed merger is conditioned upon a number of conditions including entering into a definitive agreement which is currently being negotiated by the parties. Both companies intend to conclude the negotiation as soon as practical so as to start the regulatory process with the US Securities and Exchange Commission (“SEC”) and Toronto Stock Exchange (“TSX”). A special shareholders’ meeting to approve certain aspects of the proposed merger is expected to occur during the third quarter of 2004.

Get Dragon Pharma Steroids

Dragon Pharma has provided our customers the highest level of pharmacy services throughout the continuum of the overall healthcare system: Legal Oxymetholon for Sale.

No Tags

1666 total views, 1 today


  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

  • Dragon Launches EPO Into the Brazilian Market

    Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]

  • Dragon Signs Licensing Agreement for Korea

    Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics